Clinical Trial Detail

NCT ID NCT02211014
Title An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

multiple myeloma

Therapies

Acalabrutinib

Dexamethasone

Age Groups: adult

No variant requirements are available.